Tools   Select Another Resource Report Type

http://www.onestudy.org/

Consortium aiming to produce regulatory T cells that are compatible with a kidney transplant patient''''s immune system, as a measure to suppress the body''''s natural immune response against a transplanted organ. If successful, this approach will reduce a transplantation patient''''s life-long dependency on immune suppressing drugs, many of which are often associated with undesirable side effects and can limit the patient''''s daily routine. The consortium goals are to develop and conduct clinical trials of various immunoregulatory T-cell-based products in organ transplantation recipients, allowing a direct comparison of the safety, clinical practicality and therapeutic efficacy of each cell type. The central focus of the project is to: # Production and manufacture of distinct populations of hematopoietic immunoregulatory T cells # Comparatively study the tolerogenic characteristics of these regulatory cell types # Test these cell therapy products side by side in a clinical trial living donor renal transplant recipients The first workstream will work with different T regulatory cell, tolerogenic DC and suppressive macrophage cell products that are currently in development. In addition to these therapeutics, another goal of this workstream is to develop a cell tracking technology that assesses pharmacodynamics and pharmacokinetics of these cell-based therapies. The second workstream is focused on designing and conducting a cell therapy based clinical trial in renal transplantation, taking into consideration ethics, concurrent immunosuppressive drug use, state-of-the-art immune monitoring, innovative all-in-one data capturing systems, and pharmacovigilance. The goal is to have a comparative evaluation of hematopoietic cell therapy safety in renal transplantation. The third workstream aims to learn more about the specific comparative characteristics of suppressive cell types and to use this knowledge to improve later trial designs and foster novel ideas for new or improved suppressive / tolerogenic cell population.

Proper citation: ONE Study (RRID:SCR_003886) Copy   

•   Source: SciCrunch Registry

http://www.transformproject.eu/wp-content/uploads/documents/cdim.owl

A global mediation model expressed as an ontology for use in the primary care domain. It uses a realist approach employing Basic Formal Ontology (BFO v1.1) as an upper ontology. Other ontologies were imported or specialized to give deeper definition to the concepts in the domain. These included OGMS, IAO and VSO. The CDIM ontology includes concepts that are especially important to primary care (e.g. episode of care or reason for encounter), but also others to handle temporality in queries (e.g. the start and beginning of processes). The owl file provided for download is the merged file created directly in Prot��g�� through the Refactor/Merge ontologies tool in order to facilitate the load of CDIM in LexEVS for use in the unified interoperability framework.

Proper citation: TRANSFoRm Clinical Data Integration Model (RRID:SCR_003885) Copy   

•   Source: SciCrunch Registry

http://www.orbitoproject.eu/

Project that aims to increase understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients over a range of clinically relevant conditions. The integration of in vitro and in silico approaches will provide a biopharmaceutics toolkit, validated using clinical data, to accelerate drug development. Ultimately, the project will help to facilitate and speed up the formulation development process and significantly reduce the need for animal experiments in this area as well as for human clinical studies in the future. For patients, the main benefit will be in the form of high quality medicines where the dose required is well calculated and is released in a way that consistently provides an optimal clinical effect.

Proper citation: ORBITO (RRID:SCR_003876) Copy   

•   Source: SciCrunch Registry

http://www.atheroremo.org/

Project targeting vulnerable plaques causing unexpected acute myocardial infarcts and sudden cardiac deaths by identifying and validating novel drug targets as well as devising and validating diagnostic tests. It has been designed to advance the present knowledge on the role of inflammatory remodeling in the different stages of atherosclerosis. It will also provide important knowledge for the development of strategies for prevention and clinical management of vascular diseases.

Proper citation: AtheroRemo (RRID:SCR_003831) Copy   

•   Source: SciCrunch Registry

http://www.innomed-addneuromed.com/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9,2023. Project portal for a cross European study designed to find biomarkers, or tests, for Alzheimer's disease. Its objectives are to produce and improve experimental models of Alzheimer's for biomarker discovery and to identify a biomarker for Alzheimer's disease suitable for diagnosis, prediction, and monitoring disease progression for use in clinical trials and in clinical practice. The baseline dataset database was scheduled to be completed and locked in 2008 and become available to researchers by 2009. Requests to access the data will be reviewed by the scientific projects committee.

Proper citation: AddNeuroMed (RRID:SCR_003819) Copy   

•   Source: SciCrunch Registry

http://www.mrc-cbu.cam.ac.uk/

Unit studying human cognition and the brain with about 90 researchers and postgraduate students investigating topics such as attention, emotion, language and memory. They are developing new treatments for depression, improving hearing through cochlear implants, and helping children to overcome memory problems. With a large collection of scientists engaged in both basic and translational research on the mind and brain, the Unit provides an exceptional training and academic environment that benefits postgraduate students and researchers at all levels. A significant part of their research makes use of brain imaging and they have excellent on-site facilities for magnetic resonance imaging (MRI) magnetoencephalography (MEG) and electroencephalography (EEG). They also have clinical facilities at Addenbrooke's Hospital. The Unit has close links both with the hospital and with Cambridge University.

Proper citation: MRC Cognition and Brain Sciences Unit (RRID:SCR_003818) Copy   

•   Source: SciCrunch Registry

https://www.kidney.org/

Organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease. Initiatives include public and professional education, kidney health screenings, research, and patient services. They publish a number of scientific journals including the American Journal of Kidney Diseases, Advances in Chronic Kidney Disease and the Journal of Renal Nutrition. The NKF also publishes the Kidney Dialysis Outcomes Quality Initiative K/DOQI, a comprehensive set of clinical practice guidelines. (Adapted from Wikipedia)

Proper citation: National Kidney Foundation (RRID:SCR_003990) Copy   

•   Source: SciCrunch Registry

http://medibeacon.com/

A commercial optical diagnostic company focused on providing clinicians with critical information to improve patient care. The Optical Renal Function Monitor (ORFM) is their first product platform and is focused on real-time, easy to use, and cost-effective monitoring of kidney function. Their non-invasive monitoring technology works in a similar fashion to pulse oximetry by using a light sensor placed on the skin. After the sensor has been placed, a proprietary biocompatible tracer is administered. The system can then monitor the patient''s real-time point-of-care kidney function. This information will allow for earlier detection of renal issues enabling clinicians to provide earlier, and hence more effective interventions. MediBeacon has created a research grade technique that is clinically applicable for real-time point-of-care Glomerular Filtration Rate measurement (mGFR). MediBeacon has invented a fluorescent tracer agent (MB-102) that is removed from the blood exclusively by the GFR mechanism of the kidneys. Together with their non-invasive detection device, this will deliver a real-time point-of-care measurement of GFR.

Proper citation: MediBeacon (RRID:SCR_003987) Copy   

•   Source: SciCrunch Registry

http://www.davita.com/

Healthcare company. Commercial dialysis provider with offerings that include in-center hemodialysis, in-center nocturnal dialysis, peritoneal dialysis, home hemodialysis, vascular access management, chronic kidney disease education, and renal diet assistance. Information on dialysis and chronic kidney disease, including informative articles and animated learning modules, and recipes for the dialysis diet are also available. Take advantage of their discussion forum, Find a Dialysis Center tool, DaVita GFR Calculator and more.

Proper citation: DaVita (RRID:SCR_003980) Copy   

•   Source: SciCrunch Registry

http://www.fastbiomedical.com/

A clinical stage company developing a timely, precise, and convenient method for measuring plasma volume and glomerular filtration rate (GFR). They focus on development and commercialization of a patented technology for quantifying clinically relevant parameters that have been challenging or impossible to measure in the past. The company is currently developing technology for quantifying volume status and kidney function in a clinically actionable timeframe. Their technology could have a significant impact on the treatment of patients with acute kidney injury (AKI) and chronic kidney disease (CKD).

Proper citation: FAST BioMedical (RRID:SCR_003983) Copy   

•   Source: SciCrunch Registry

http://www.chemocentryx.com/

A biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Each drug candidate is a small molecule designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: ChemoCentryx (RRID:SCR_003976) Copy   

•   Source: SciCrunch Registry

http://www.crbard.com/

A multinational developer, manufacturer, and marketer of medical technologies specializing in the manufacture of vascular, urology, oncology and surgical specialty products. BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs. Bard is perhaps best known for having introduced the Foley catheter. (Adapted from Wikipedia)

Proper citation: C. R. Bard (RRID:SCR_003975) Copy   

•   Source: SciCrunch Registry

http://sharpentrials.com/

THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021.Organization that uses metabolomics to provide pharmaceutical companies with clinically relevant and practical insight into drug response and safety for renal and cardiovascular diseases, obesity and diabetes. Their combination of skills to achieve exhaustive understanding of a disease along with detailed clinical insights, signature panel of urine-based metabolomic biomarkers, proprietary metabolomics and computational expertise will accelerate the speed and success rate of drug development. ClinMet helps drug developers to efficiently transform promising compounds into safe and effective medicines. Their efficacy and toxicity indices enable pharmaceutical companies to make better clinical trial-related decisions and provide an increased understanding of a drug''s mechanism of action.

Proper citation: ClinMet (RRID:SCR_003979) Copy   

•   Source: SciCrunch Registry

http://www.bcchf.ca/

Funding resource that raises funds to support BC Children's Hospital, Sunny Hill Health Centre for Children and the Child and Family Research Institute. The Foundation also works with Sunny Hill's Board of Directors to manage the Sunny Hill Foundation for Children. In 2013, BC Children's Hospital Foundation received donations from more than 150,000 people and had revenues of over $83 million.

Proper citation: BC Childrens Hospital Foundation (RRID:SCR_003925) Copy   

•   Source: SciCrunch Registry

http://www.icr.ac.uk/

Academic cancer research center, a postgrad college, and a charity in the United Kingdom that is making discoveries that defeat cancer. With their partners The Royal Marsden NHS Foundation Trust they form the largest comprehensive cancer center in Europe and perform high quality and original basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide. The ICR offers comprehensive, modern facilities for research and studentships supported by the Wellcome Trust, MRC, CRUK and EPSRC and the ICR''s own resources which are awarded on a competitive basis. The ICR offers postgraduate research degrees (MPhil, PhD and MD (Res)) and a modular postgraduate taught degree in oncology aimed at clinicians undertaking specialist training in the field of Clinical or Medical Oncology leading to a Postgraduate Certificate, Postgraduate Diploma or MSc in Oncology.

Proper citation: Institute of Cancer Research (RRID:SCR_003912) Copy   

•   Source: SciCrunch Registry

http://www.orion.fi/en/

A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.

Proper citation: Orion (RRID:SCR_003911) Copy   

•   Source: SciCrunch Registry

http://www.simcyp.com/

Research based company providing predictive pharmacokinetic and pharmacodynamic tools, workshops and consultancy services. Their user-friendly simulator and databases predict drug absorption, clearance, distribution and metabolic drug-drug interactions from in vitro data. Simcyp's clients include major global pharmaceutical and bioscience companies, leading academic institutes and regulatory authorities. These clients form the Simcyp Consortium, which together with independent International Scientific Advisory Board, guide scientific development at Simcyp.Simcyp was acquired by Certara in 2012.

Proper citation: Simcyp (RRID:SCR_003944) Copy   

•   Source: SciCrunch Registry

http://www.bdi.ie/

An academic-business-clinical partnership that sponsors research programs focused on the development of next-generation biomedical diagnostic devices. They aim to transform healthcare by pioneering advances in the science and technology of diagnostics and by translating these advances into clinical use. Building on key scientific insights, the BDI will now apply its established capabilities to create integrated Point-of-Care solutions, which will have major impacts on diagnosing disease and sustaining human health.

Proper citation: Biomedical Diagnostics Institute (RRID:SCR_004022) Copy   

•   Source: SciCrunch Registry

http://www.aami.org/

A nonprofit organization made up of a diverse community of healthcare technology professionals that support the healthcare community in the development, management, and use of safe and effective medical technology. It is the primary source of consensus and timely information on medical instrumentation and technology. * AAMI is the primary resource for the industry, the professions, and government for national and international standards. * AAMI provides multidisciplinary leadership and programs that enhance the ability of the professions, healthcare institutions, and industry to understand, develop, manage, and use medical instrumentation and related technologies safely and effectively. * AAMI helps members: contain costs, keep informed of new technology and policy developments, add value in healthcare organizations, and improve professional skills and enhance patient care. * AAMI provides a unique and critical forum for members who cover a complete range of interests, from clinical and biomedical engineers and technicians, physicians, nurses, and hospital administrators, to educators and researchers, manufacturers, distributors, government representatives and other healthcare professionals with an interest in medical devices. * AAMI fulfills its mission through: ** continuing education, conferences ** certification of healthcare technical specialists ** the publication of technical documents, periodicals, books, software.

Proper citation: Association for the Advancement of Medical Instrumentation (RRID:SCR_003973) Copy   

•   Source: SciCrunch Registry

http://www.apheresis.org/

An organization of physicians, scientists, and allied health professionals whose mission is to advance apheresis medicine for patients, donors and practitioners through education, evidence-based practice, research and advocacy. ASFA represents a broad range of professionals involved in: donor apheresis, apheresis in transplantation & therapeutic apheresis.

Proper citation: American Society for Apheresis (RRID:SCR_003967) Copy   

•   Source: SciCrunch Registry